References
- Chesnut C, McClung M, Ensrud K, Bell N, Genant H, Harris S, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodelling. Am J Med. 1995; 99: 144–52
- Guanabens N, Pares A, Monega A, Peris P, Pons F, Alvarez L, et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 1997; 113: 219–24
- Groen P, Lubbe D, Hirsch L, Daifotis A, Stephenson W, Freedholm D, et al. Oesophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016–21
- Lowe C, Depew W, Vanner S, Paterson W, Meddings J. Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol 2000; 95: 634–40